Research programme: dengue fever DNA vaccines - Inovio

Drug Profile

Research programme: dengue fever DNA vaccines - Inovio

Latest Information Update: 10 Aug 2015

Price : $50

At a glance

  • Originator Inovio Biomedical Corporation
  • Developer Inovio Pharmaceuticals
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Dengue

Most Recent Events

  • 10 Aug 2015 Preclinical development is ongoing in USA
  • 29 Jul 2015 Pharmacodynamics data from a preclinical study in Dengue released by Inovio Pharmaceuticals
  • 02 Nov 2010 Inovio receives grant under The Patient Protection and Affordable Care Act of 2010 (PPACA) for development of its dengue vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top